Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: A prospective study

Annals of Surgery

Volumn 243, Issue 1, 2006, Pages 58-63

  Rossi, Mauro ^a   Barreca, Marco ^a   De Bortoli, Nicola ^b   Renzi, Cristina ^c   Santi, Stefano ^a   Gennai, Alessandro ^a   Bellini, Massimo ^b   Costa, Francesco ^b   Conio, Massimo ^d   Marchi, Santino ^b  

^a Department of General Surgery IV   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d Bordigheria Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE SEVERITY; DYSPLASIA; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; LAPAROSCOPIC SURGERY; LOW GRADE DYSPLASIA; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RISK FACTOR; SEX RATIO; STOMACH ACID SECRETION; STOMACH FUNDOPLICATION;

ADULT; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ENZYME INHIBITORS; ESOPHAGUS; FEMALE; FUNDOPLICATION; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; PROTON PUMPS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 30144438411     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000194085.56699.db     Document Type: Article

References (24)

1. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987;92:118-124.
2. Csendes A, Smok G, Burdiles P, et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus. 2003;16:24-28.
3. Pera M, Cameron AJ, Trastec VF, et al. Increasing incidence of adenocarcinoma of esophagus and esophagogastric junction in west. Gastroenterology. 1993;104:510-513.
4. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology. 1995;109:1541-1546.
5. Falk JW. Barrett's esophagus. Gastroenterology. 2002;122:1569-1591.
6. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus: an overrated risk? Gastroenterology. 1984;87:927-933.
7. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313:857-859.
8. Fitzgerald RC, Saeed IT, Khoo D, et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci. 2001;46:1892-1898.
9. Samplimer RE. Practice Parameters Committee of the American College of Gastroenterology: practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 1998;93:1028-1032.
10. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg. 2003;237:291-298.
11. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
12. Rydell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Hum Pathol. 1983;14:931-938.
13. Peters FTM, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: a randomised double blind study. Gut. 1999;45:489-494.
14. Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther. 1998;12:893-897.
15. Sharma P, Morales TG, Bhattacharyya A, et al. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol. 1998;93:332-335.
16. Gurski RR, Peters JH, Hagen JA, et al. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg. 2003;196:706-712.
17. Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238:458-464.
18. Weston AP, Sharma P, Topalosky M, et al. Low-grade dysplasia in Barrett's esophagus: variable fate during long-term prospective follow up. Gastroenterology. 1999;116:1349A.
19. Sontag SJ, Schnell T, Chejfec G, et al. Barrett's, low-grade dysplasia and fear, yearly endoscopy in not justified: surveillance every 2-3 years detects all cancer early. Gastroenterology. 1999;116:1381A.
20. Richter JE. What is the long-term significance of low-grade dysplasia? In: Giuli R, ed. Barrett's Esophagus, vol. 1. Paris: Edition John Libbey Eurotext, 2003:306.
21. Sharma P, Falk G, Weston A, et al. Natural history of low-grade dysplasia: an infrequent finding which usually regresses. Preliminary results from the Barrett's Esophagus Study. Gastroenterology. 2002;122:A20.
22. Drewitz DJ, Sampliner RE, Garewal HS, et al. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
23. Csendes A, Burdiles P, Braghetto I, et al. Dysplasia and adenocarcinoma after classic antireflux surgery in patients with Barrett's esophagus: the need for long-term subjective and objective follow-up. Ann Surg. 2002;235:178-185.
24. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus: incidence of dysplasia and adenocarcinoma. A prospective study. Am J Gastroenterol. 2003;98:1931-1939.